Refine
Year of publication
Document Type
- Article (27)
Has Fulltext
- yes (27)
Is part of the Bibliography
- no (27)
Keywords
- NK cells (4)
- NK cell (3)
- chimeric antigen receptor (3)
- natural killer cells (3)
- CD19 (2)
- Cancer (2)
- Immunotherapy (2)
- bio imaging (2)
- bioluminescence (2)
- cell therapy (2)
- immune reconstitution (2)
- immunotherapy (2)
- mesenchymal stromal/stem cells (2)
- natural killer cell (2)
- qRT-PCR (2)
- rhabdomyosarcoma (2)
- tracking (2)
- Apoptosis (1)
- Ataxia telangiectasia (1)
- Atm (1)
- BV6 (1)
- CAR (1)
- CAR-NK cell (1)
- CAR-T cell (1)
- CD16 (1)
- CD3/CD19 depletion (1)
- CD4+ T cells (1)
- CD56 (1)
- CIK cell (1)
- CIK cells (1)
- DC-NK cell interaction (1)
- ERBB2 (HER2/neu) (1)
- Forkhead box (1)
- GVHD (1)
- GVL (1)
- Glivec® (1)
- GvL (1)
- HDACi (1)
- HSCT (1)
- IL-15 (1)
- IL-21 (1)
- IMiD® (1)
- MicroRNAs (1)
- NK cell subset (1)
- NK-92 (1)
- NKG2A blocking (1)
- Natural killer cells (1)
- PCR (1)
- Paediatric cancer (1)
- Preclinical research (1)
- RD cells (1)
- RH30 cells (1)
- Regulatory T cells (1)
- SARS-CoV-2 (1)
- SARS-CoV-2-specific T cells (1)
- SCT (1)
- T cell (1)
- T cell receptors (1)
- T cells (1)
- T helper 17 cells (1)
- T helper cell differentiation (1)
- TCR signaling cascade (1)
- TKI (1)
- Thymocytes (1)
- Thymus (1)
- Translational research (1)
- Tumour immunology (1)
- aGVHD (1)
- activation receptors (1)
- acute and chronic graft versus host disease (a/c GVHD) (1)
- acute kidney injury (1)
- acute lymphoblastic leukemia (1)
- adoptive cell therapy (1)
- adoptive immunotherapy (1)
- allogeneic hematopoietic stem cell transplantation (aHSCT) (1)
- allogeneic transplantation (1)
- alpharetroviral vector (1)
- anti-angiogenic therapy (1)
- autologous stem cell transplantation (1)
- bacterium (1)
- basic leucine zipper transcription factor ATF-like (1)
- bortezomib (1)
- cellular therapies (1)
- cellular therapy (1)
- checkpoint inhibition (1)
- chemokine receptor 4 (1)
- children (1)
- colitis (1)
- congenic mice (1)
- cytokine-induced killer cells (1)
- dendritic cells (1)
- ex vivo expansion (1)
- ex vivo stimulation (1)
- fully human (1)
- fungus (1)
- gene therapy (1)
- glioblastoma (1)
- granulocytemacrophage colony-stimulating factor (1)
- huCAR19 (1)
- immune therapy (1)
- innate lymphoid cells (1)
- interleukin-23 receptor (1)
- intestinal graft-versushost disease (1)
- intracellular trafficking (1)
- lenalidomide (1)
- lentiviral vector (1)
- macrophage polarization (1)
- metabolism (1)
- microbiome (1)
- multiple myeloma (1)
- natural killer cell cultivation (1)
- natural killer cell cytotoxicity (1)
- natural killer cell expansion (1)
- natural killer cell therapy (1)
- neuroblastoma (1)
- reference values (1)
- renal failure (1)
- retinoic acid-related orphan receptor gamma t (1)
- second mitochondria-derived activator of caspases mimetic (1)
- thalidomide (1)
- therapy resistance (1)
- transcription factors (1)
- transgenically augmented CAR NK cell (1)
- tumor angiogenesis (1)
- tumor microenvironment (1)
- vaccination (1)
- virus (1)
Institute
- Medizin (27)
- Georg-Speyer-Haus (2)
Glioblastoma multiforme (GBM) is treated by surgical resection followed by radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of recurrent GBM; however, innate immune cells have been identified as instigators of resistance to bevacizumab treatment. We identified angiopoietin‐2 (Ang‐2) as a potential target in both naive and bevacizumab‐treated glioblastoma. Ang‐2 expression was absent in normal human brain endothelium, while the highest Ang‐2 levels were observed in bevacizumab‐treated GBM. In a murine GBM model, VEGF blockade resulted in endothelial upregulation of Ang‐2, whereas the combined inhibition of VEGF and Ang‐2 leads to extended survival, decreased vascular permeability, depletion of tumor‐associated macrophages, improved pericyte coverage, and increased numbers of intratumoral T lymphocytes. CD206+ (M2‐like) macrophages were identified as potential novel targets following anti‐angiogenic therapy. Our findings imply a novel role for endothelial cells in therapy resistance and identify endothelial cell/myeloid cell crosstalk mediated by Ang‐2 as a potential resistance mechanism. Therefore, combining VEGF blockade with inhibition of Ang‐2 may potentially overcome resistance to bevacizumab therapy.
Natural killer (NK) cells play an important role following allogeneic hematopoietic stem cell transplantation (HSCT) exerting graft-versus-leukemia/tumor effect and mediating pathogen-specific immunity. Although NK cells are the first donor-derived lymphocytes reconstituting post-HSCT, their distribution of CD56++CD16− (CD56bright), CD56++CD16+ (CD56intermediate=int), and CD56+CD16++ (CD56dim) NK cells is explicitly divergent from healthy adults, but to some extent comparable to the NK cell development in early childhood. The proportion of CD56bright/CD56int/CD56dim changed from 15/8/78% in early childhood to 6/4/90% in adults, respectively. Within this study, we first compared the NK cell reconstitution post-HSCT to reference values of NK cell subpopulations of healthy children. Afterward, we investigated the reconstitution of NK cell subpopulations post-HSCT in correlation to acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD) as well as to viral infections. Interestingly, after a HSCT follow-up phase of 12 months, the distribution of NK cell subpopulations largely matched the 50th percentile of the reference range for healthy individuals. Patients suffering from aGvHD and cGvHD showed a delayed reconstitution of NK cells. Remarkably, within the first 2 months post-HSCT, patients suffering from aGvHD had significantly lower levels of CD56bright NK cells compared to patients without viral infection or without graft versus host disease (GvHD). Therefore, the amount of CD56bright NK cells might serve as an early prognostic factor for GvHD development. Furthermore, a prolonged and elevated peak in CD56int NK cells seemed to be characteristic for the chronification of GvHD. In context of viral infection, a slightly lower CD56 and CD16 receptor expression followed by a considerable reduction in the absolute CD56dim NK cell numbers combined with reoccurrence of CD56int NK cells was observed. Our results suggest that a precise analysis of the reconstitution of NK cell subpopulations post-HSCT might indicate the occurrence of undesired events post-HSCT such as severe aGvHD.values
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. Currently, more than 500 CAR-T and 17 CAR-NK cell trials are being conducted worldwide including the four CAR-T cell products Kymriah, Yescarta, Tecartus and Breyanzi, which are already available on the market. Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany.
Cellular therapy has entered the daily clinical life with the approval of CAR T cell therapeutics and dendritic cell (DCs) vaccines in the US and the EU. In addition, numerous other adoptive cellular products, including natural killer (NK) cells, are currently evaluated in early phase I/ II clinical trials for the treatment of cancer patients. Despite these promising accomplishments, various challenges remain to be mastered in order to ensure sustained therapeutic success. These include the identification of strategies by which tumor cells escape the immune system or establish an immunosuppressive tumor microenvironment (TME). As part of the innate immune system, DCs and NK cells are both present within the TME of various tumor entities. While NK cells are well known for their intrinsic anti-tumor activity by their cytotoxicity capacities and the secretion of pro-inflammatory cytokines, the role of DCs within the TME is a double-edged sword as different DC subsets have been described with either tumor-promoting or -inhibiting characteristics. In this review, we will discuss recent findings on the interaction of DCs and NK cells under physiological conditions and within the TME. One focus is the crosstalk of various DC subsets with NK cells and their impact on the progression or inhibition of tumor growth. In addition, we will provide suggestions to overcome the immunosuppressive outcome of the interaction of DCs and NK cells within the TME.
The promising development of adoptive immunotherapy over the last four decades has revealed numerous therapeutic approaches in which dedicated immune cells are modified and administered to eliminate malignant cells. Starting in the early 1980s, lymphokine activated killer (LAK) cells were the first ex vivo generated NK cell-enriched products utilized for adoptive immunotherapy. Over the past decades, various immunotherapies have been developed, including cytokine-induced killer (CIK) cells, as a peripheral blood mononuclear cells (PBMCs)-based therapeutic product, the adoptive transfer of specific T and NK cell products, and the NK cell line NK-92. In addition to allogeneic NK cells, NK-92 cell products represent a possible “off-the-shelf” therapeutic concept. Recent approaches have successfully enhanced the specificity and cytotoxicity of T, NK, CIK or NK-92 cells towards tumor-specific or associated target antigens generated by genetic engineering of the immune cells, e.g., to express a chimeric antigen receptor (CAR). Here, we will look into the history and recent developments of T and NK cell-based immunotherapy.
A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets
(2018)
NKp46 (CD335) is a surface receptor shared by both human and mouse natural killer (NK) cells and innate lymphoid cells (ILCs) that transduces activating signals necessary to eliminate virus-infected cells and tumors. Here, we describe a spontaneous point mutation of cysteine to arginine (C14R) in the signal peptide of the NKp46 protein in congenic Ly5.1 mice and the newly generated NCRB6C14R strain. Ly5.1C14R NK cells expressed similar levels of Ncr1 mRNA as C57BL/6, but showed impaired surface NKp46 and reduced ability to control melanoma tumors in vivo. Expression of the mutant NKp46C14R in 293T cells showed that NKp46 protein trafficking to the cell surface was compromised. Although Ly5.1C14R mice had normal number of NK cells, they showed an increased number of early maturation stage NK cells. CD49a+ILC1s were also increased but these cells lacked the expression of TRAIL. ILC3s that expressed NKp46 were not detectable and were not apparent when examined by T-bet expression. Thus, the C14R mutation reveals that NKp46 is important for NK cell and ILC differentiation, maturation and function.